

# Paolo Parini

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5526303/paolo-parini-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

2,409  
citations

20  
h-index

48  
g-index

61  
ext. papers

3,125  
ext. citations

6.7  
avg, IF

5.13  
L-index

#	Paper	IF	Citations
54	Inflammaging: a new immune-metabolic viewpoint for age-related diseases. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 576-590	15.2	831
53	The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. <i>Cell Reports</i> , <b>2015</b> , 10, 326-338	10.6	244
52	ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. <i>Circulation</i> , <b>2004</b> , 110, 2017-23	16.7	165
51	Accumulation of foam cells in liver X receptor-deficient mice. <i>Circulation</i> , <b>2002</b> , 106, 1147-53	16.7	153
50	Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. <i>Cell Metabolism</i> , <b>2010</b> , 12, 187-93	24.6	132
49	Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. <i>European Journal of Clinical Investigation</i> , <b>2006</b> , 36, 98-104	4.6	99
48	Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism. <i>Biology</i> , <b>2015</b> , 4, 104-32	4.9	57
47	Does statins promote vascular calcification in chronic kidney disease?. <i>European Journal of Clinical Investigation</i> , <b>2017</b> , 47, 137-148	4.6	48
46	Can LDL cholesterol be too low? Possible risks of extremely low levels. <i>Journal of Internal Medicine</i> , <b>2017</b> , 281, 534-553	10.8	41
45	Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57BL/6 female mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2010</b> , 298, E167-78	6	41
44	Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2011</b> , 301, E210-22	6	41
43	Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells. <i>Endocrinology</i> , <b>1995</b> , 136, 3767-73	4.8	36
42	Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR $\alpha$ . <i>Nature Communications</i> , <b>2019</b> , 10, 1684	17.4	27
41	Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. <i>PLoS ONE</i> , <b>2014</b> , 9, e113619	3.7	26
40	Control of ACAT2 liver expression by HNF1. <i>Journal of Lipid Research</i> , <b>2005</b> , 46, 1868-76	6.3	26
39	Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. <i>Journal of Internal Medicine</i> , <b>2011</b> , 269, 333-9	10.8	25
38	Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2016</b> , 36, 787-91	4	25

37	Development of drug-loaded immunoliposomes for the selective targeting and elimination of rosetting Plasmodium falciparum-infected red blood cells. <i>Journal of Controlled Release</i> , <b>2016</b> , 241, 57-67	11.7	21
36	Emerging role of thyroid hormone metabolites. <i>Acta Physiologica</i> , <b>2016</b> , 217, 184-216	5.6	21
35	Control of ACAT2 liver expression by HNF4{alpha}: lesson from MODY1 patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 1235-41	9.4	21
34	Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e93552	3.7	20
33	ER $\alpha$ activation in obesity improves whole body metabolism via adipose tissue function and enhanced mitochondria biogenesis. <i>Molecular and Cellular Endocrinology</i> , <b>2019</b> , 479, 147-158	4.4	20
32	Sex-specific lipid molecular signatures in obesity-associated metabolic dysfunctions revealed by lipidomic characterization in ob/ob mouse. <i>Biology of Sex Differences</i> , <b>2019</b> , 10, 11	9.3	18
31	Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 1200-6	9.4	18
30	Cholesteryl esters and ACAT. <i>European Journal of Lipid Science and Technology</i> , <b>2012</b> , 114, 624-633	3	17
29	ACAT2 and human hepatic cholesterol metabolism: identification of important gender-related differences in normolipidemic, non-obese Chinese patients. <i>Atherosclerosis</i> , <b>2009</b> , 207, 266-71	3.1	17
28	The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 420-432	6.3	15
27	RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2015</b> , 82, 186-93	5.8	15
26	Intestinal PPAR $\beta$ signalling is required for sympathetic nervous system activation in response to caloric restriction. <i>Scientific Reports</i> , <b>2016</b> , 6, 36937	4.9	15
25	The thyroid receptor $\beta$ modulator GC-1 reduces atherosclerosis in ApoE deficient mice. <i>Atherosclerosis</i> , <b>2014</b> , 237, 544-54	3.1	15
24	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 77-87	4.9	15
23	Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009876	6	12
22	Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy. <i>Journal of Internal Medicine</i> , <b>2019</b> , 286, 660-675	10.8	11
21	Potential Role of Thyroid Receptor $\beta$ Agonists in the Treatment of Hyperlipidemia. <i>Drugs</i> , <b>2017</b> , 77, 1613-1621	16.21	11
20	The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 1851-1858	14.6	11

19	Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2016</b> , 1861, 51-59	5	10
18	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 66	7.7	9
17	Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 499-502	3.1	9
16	Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice. <i>Archives of Biochemistry and Biophysics</i> , <b>2008</b> , 471, 63-71	4.1	8
15	Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans. <i>Hepatology</i> , <b>2020</b> , 72, 656-670	11.2	6
14	A global network for network medicine. <i>Npj Systems Biology and Applications</i> , <b>2020</b> , 6, 29	5	6
13	Genetic depletion of Soat2 diminishes hepatic steatosis via genes regulating de novo lipogenesis and by GLUT2 protein in female mice. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1016-1022	3.3	6
12	Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	6
11	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , <b>2021</b> , 322, 77-81	3.1	5
10	Role of TG-interacting factor (Tgif) in lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2015</b> , 1851, 9-12	5	4
9	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , <b>2021</b> , 50, 401-411	1.9	4
8	Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients. <i>Journal of Lipid Research</i> , <b>2015</b> , 56, 1633-9	6.3	3
7	Overexpression of transforming growth factor β-induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. <i>Atherosclerosis</i> , <b>2018</b> , 275, 246-255	3.1	3
6	Diiodothyronines regulate metabolic homeostasis in primary human hepatocytes by modulating mTORC1 and mTORC2 activity. <i>Molecular and Cellular Endocrinology</i> , <b>2020</b> , 499, 110604	4.4	3
5	Generation of new hepatocyte-like in vitro models better resembling human lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2020</b> , 1865, 158659	5	2
4	Changes in gluconeogenesis and intracellular lipid accumulation characterize uremic human hepatocytes ex vivo. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 310, G952-61	5.1	2
3	It takes two to dance the VBHC tango: A multiple case study of the adoption of value-based strategies in Sweden and Brazil. <i>Social Science and Medicine</i> , <b>2021</b> , 282, 114145	5.1	2
2	Vasculoprotective properties of plasma lipoproteins from brown bears ( <i>Ursus arctos</i> ). <i>Journal of Lipid Research</i> , <b>2021</b> , 62, 100065	6.3	1

- 1 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. *Atherosclerosis*, **2021**, 338, 55-63 3.1 0